RECRUITING

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Talk to us

Conditions

Non-small Cell Lung Cancer (NSCLC)

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-squamous non-small cell lung cancer (NSCLC). Participants in this study have NSCLC that has continued to progress on prior treatment with EGFR tyrosine kinase inhibitors (TKIs). The primary hypotheses of this study are that sacituzumab tirumotecan is better than platinum-based doublet chemotherapy (pemetrexed and carboplatin) in regard to progression-free survival (PFS) and overall survival (OS).

Official Title

A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors

Quick Facts

Study Start:2024-06-11
Study Completion:2030-06-14
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06305754

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Histologically or cytologically confirmed diagnosis of advanced-stage nonsquamous non-small cell lung cancer (NSCLC).
  2. * Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to Grade \<1 or baseline.
  3. * Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load.
  4. * Participants with history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable.
  5. * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy.
  6. * Life expectancy of at least 3 months.
  1. * Predominantly squamous cell histology NSCLC.
  2. * History of second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years.
  3. * Grade \>2 peripheral neuropathy.
  4. * History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or corneal disease that prevents/delays corneal healing.
  5. * Active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease.
  6. * Uncontrolled, or significant cardiovascular disease or cerebrovascular disease.
  7. * Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids.
  8. * Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.
  9. * Received radiation therapy to the lung that is \>30 Gray within 6 months of the first dose of study intervention.
  10. * Known active central nervous system metastases and/or carcinomatous meningitis.
  11. * Active infection requiring systemic therapy.
  12. * History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
  13. * HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
  14. * Concurrent active HBV and HCV infection.
  15. * History of allogeneic tissue/solid organ transplant.
  16. * Participants who have not adequately recovered from major surgery or have ongoing surgical complications.

Contacts and Locations

Study Contact

Toll Free Number
CONTACT
1-888-577-8839
Trialsites@msd.com

Principal Investigator

Medical Director
STUDY_DIRECTOR
Merck Sharp & Dohme LLC

Study Locations (Sites)

Mid Florida Hematology and Oncology Center ( Site 0005)
Orange City, Florida, 32763
United States
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0003)
Marietta, Georgia, 30060
United States
Astera Cancer Care ( Site 0032)
East Brunswick, New Jersey, 08816
United States
Millennium Research & Clinical Development ( Site 0035)
Houston, Texas, 77090
United States

Collaborators and Investigators

Sponsor: Merck Sharp & Dohme LLC

  • Medical Director, STUDY_DIRECTOR, Merck Sharp & Dohme LLC

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-06-11
Study Completion Date2030-06-14

Study Record Updates

Study Start Date2024-06-11
Study Completion Date2030-06-14

Terms related to this study

Additional Relevant MeSH Terms

  • Non-small Cell Lung Cancer (NSCLC)